SEER Inquiry System - Search

First Course Treatment/Immunotherapy--Other Therapy:  Should all therapies given as part of a clinical trial be coded as Other Therapy (NAACCR #1420), or only those that cannot be classified in one of the other treatment categories (systemic therapy, surgery, radiation) or as ancillary treatments?  Does it matter what is listed in SEER*Rx under Primary Sites or Remarks regarding FDA approvals?  See Discussion.

Solid Tumor Rules/Multiple Primaries--Lung:  How many cases should be abstracted for a patient with 2022 wedge biopsy of right upper lobe acinar predominant lung adenocarcinoma and wedge biopsy of right lower lobe lepidic predominant adenocarcinoma if there is concern for diffuse spread throughout the lungs secondary to the lymphangitic carcinomatosis and possible diffuse pneumonic type of adenocarcinoma? See Discussion.

Solid Tumor Rules/Multiple Primaries--Lung: How many primaries should be reported when two separate squamous cell carcinoma (SCC) tumors, one in the left upper lobe (LUL) and one in the right lower lobe (RLL), are diagnosed? The tumors are separated by an interval occurring right hilar lymph node biopsy proving metastatic pulmonary adenocarcinoma without a clear description of a corresponding interval occurring lung tumor. See Discussion.

First Course Therapy/Surgery of Primary Site--Prostate:  What is the correct surgical code for irreversible electroporation ablation of the prostate diagnosed in 2021?

SEER Manual/Reportability--Ambiguous Terminology:  Please clarify the reportability and relevant date ranges of the following ambiguous terminology: almost certainly, most certainly, and malignant until proven otherwise.  See Discussion.

SEER Manual/Laterality--Kaposi Sarcoma:  If both arms are involved with Kaposi sarcoma and no other sites, how is laterality coded?  See Discussion.

SEER Manual/First Course Treatment--Radiation Treatment Modality: How is Peptide Receptor Radionuclide Therapy (PRRT), a form of molecular therapy, coded when used to treat neuroendocrine tumors? See Discussion.

SEER Manual/First Course Treatment--Hematologic Transplant And Endocrine Procedures:  How are Surgery of Primary Site and the Hematologic Transplant And Endocrine Procedures data items coded when patient has total abdominal hysterectomy and bilateral oophorectomy for an endometrial primary during the same procedure? Also, how would these data items be coded for a vaginal primary in a surgical scenario?  See Discussion.

SEER Manual/Reportability--Appendix:  Is low-grade appendiceal mucinous neoplasm (LAMN) with peritoneal spread followed by evidence of extraperitoneal metastatic disease reportable prior to 2022?  See Discussion.

SEER Manual/Surgery of Primary Site 2023--Breast:  What instructions should be followed when the 2023 SEER Manual Appendix C 2023 Breast Surgery Codes advise to code 1 in Surgical Procedure of Other Site for a simple bilateral mastectomy but the 2023 STORE Manual does not.  See Discussion.